Has the South Korean Biotech Industry valuation changed over the past few years?

Investors are optimistic on the industry, and appear confident in long-term growth rates. The industry is trading at a PE ratio of 107x which is higher than its 3-year average PE of -398x. The industry's 3-year average PS ratio 10.1x is higher than the industry's current PS ratio of 6.0x.

How does South Korean Biotech compare with similar industries?

There is insufficient data on the sub-industries of this industry.

South Korean (KOSPI) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Mon, 04 Jul 2022	₩62.3t	₩10.7t	₩597.6b	22.4x
Wed, 01 Jun 2022	₩69.0t	₩10.6t	₩680.3b	27.8x
Fri, 29 Apr 2022	₩71.0t	₩10.0t	₩866.3b	26.7x
Sun, 27 Mar 2022	₩75.8t	₩9.9t	₩883.7b	33.3x
Tue, 22 Feb 2022	₩72.4t	₩9.4t	₩783.3b	34.1x
Thu, 20 Jan 2022	₩79.1t	₩9.4t	₩787.4b	34.4x
Sat, 18 Dec 2021	₩97.7t	₩9.4t	₩780.1b	40.8x
Mon, 15 Nov 2021	₩94.1t	₩9.2t	₩986.1b	32.9x
Wed, 13 Oct 2021	₩94.8t	₩9.2t	₩986.0b	36.2x
Fri, 10 Sep 2021	₩116.5t	₩9.3t	₩946.2b	43.2x
Sun, 08 Aug 2021	₩114.8t	₩9.3t	₩909.7b	52.6x
Sat, 01 May 2021	₩101.2t	₩9.0t	₩979.0b	41.7x
Tue, 02 Feb 2021	₩96.7t	₩8.2t	₩501.3b	49.6x
Fri, 06 Nov 2020	₩80.0t	₩7.5t	₩291.2b	32.5x
Mon, 10 Aug 2020	₩87.9t	₩6.7t	-₩13,176,736,074.00	49.2x
Sun, 03 May 2020	₩57.2t	₩6.1t	-₩304,564,934,452.00	43.6x
Wed, 05 Feb 2020	₩46.7t	₩5.8t	-₩212,594,028,191.00	41.2x
Sat, 09 Nov 2019	₩51.3t	₩5.5t	₩44.0b	37.8x
Fri, 02 Aug 2019	₩49.7t	₩5.4t	₩112.2b	40.4x


KR Market	-2.64%
Healthcare	-2.76%
Biotech	-2.12%
Biotech	-2.12%

Company	Last Price	7D	1Y	Valuation
A068270 Celltrion	₩179.00k	4.4% +₩1.0t	-31.4%	PE49.3x
A115450 HLB TherapeuticsLtd	₩13.75k	6.6% +₩26.4b	17.0%	PS9.1x
A086820 Bio SolutionLtd	₩13.65k	13.8% +₩13.2b	-56.7%	PS13.2x
A365270 Curacle	₩17.70k	5.0% +₩11.7b	n/a	PS35.7x
A235980 MedPacto	₩22.95k	2.2% +₩10.7b	-67.8%	PB8x

Jun 30

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. has obtained EU approval for its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay that is compatible with the company's fully automated 'AIOS' (All-in-One System). This is expected to help small hospitals, local clinics, and public health centers effectively identify COVID-19, influenza A and B and respiratory syncytial virus (RSV). Syndromic assay for four respiratory viruses: The Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay can detect six targets associated with the four respiratory viruses. The targets include three distinct COVID-19 genes (S, RdRp, N) to reliably identify positive cases even as new variants emerge. The test also includes two internal controls for proper sampling and testing validation. The product can deliver results within two hours when extraction-free, making it both time and cost-efficient. AIOS, which will be released in July, supports "hands-free" PCR workflows – from nucleic acid extraction to PCR setup, gene amplification and results analysis. As AIOS is a fully automated (sample in – result out) system, it can be operated by those without PCR experience. AIOS is also compact in size and has over 30 compatible assays for syndromic testing to boost efficiency and utility, in contrast to conventional automated PCR solutions in the market that are bigger and have fewer applicable assays that detect only one to three specific targets. AIOS is the world's first fully automated and "assembled" solution that composes independent and detachable instruments required for PCR, unlike other solutions that operate as a single unit. This makes AIOS convenient to use and maintain, while authorization procedures will be easier as existing instruments and assays can be applied. Such features are expected to allow small hospitals, local clinics, and public health centers to integrate AIOS into their workflows for PCR tests, which had been limited before due to lack of instruments or specialists to operate PCR solutions. Healthcare specialists have warned of a resurgence of COVID-19 as early as summer – alongside an increase in flu and cold cases – as immunity from COVID-19 vaccines wane and virus-prevention measures are eased. In response to these concerns, Seegene recently launched the 'In-life PCR' initiative to embed PCR tests into routine by increasing affordability and accessibility. It is aimed at detecting viruses especially among asymptomatic people to help end the COVID-19 outbreak as well as curb widespread transmission to prevent new pandemics. Using the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay and AIOS, Seegene hopes to establish the foundation for routine testing.

South Korean (KOSPI) Biotech Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

A226950

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

A290650

L&C Bio Co., Ltd announced that it has received KRW 60 billion in funding

A096530

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

A048530

Investor sentiment deteriorated over the past week

A068270

Investor sentiment improved over the past week

A302440

Price target decreased to ₩167,222

A049960

Investor sentiment deteriorated over the past week

A314130

First quarter 2022 earnings released: ₩673 loss per share (vs ₩549 loss in 1Q 2021)

A084990

First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021)

A235980

Price target decreased to ₩113,000

A196170

Price target decreased to ₩79,000

A115450

No independent directors

A086820

Biosolution Co.,Ltd. (KOSDAQ:A086820) agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion.

A298380

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

A149300

Apures Co., Ltd. announced that it has received KRW 2.999998485 billion in funding